Estrella Immunopharma Inc. (ESLA) Income Statement Analysis - Revenue, Earnings & Profitability Metrics - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    Estrella Immunopharma Inc...

    NASDAQ: ESLA · Real-Time Price · USD
    1.03
    -0.02 (-1.90%)
    At close: Sep 08, 2025, 3:59 PM
    0.99
    -3.88%
    After-hours: Sep 08, 2025, 07:41 PM EDT

    Estrella Immunopharma Income Statement

    Financials in USD. Fiscal year is July - June.

    undefined peaked at n/a in undefined and hit its lowest at n/a in undefined. Over the past five years, it has declined by undefined%.

    Fiscal Year FY 2023 FY 2022 FY 2021
    Period Ending Jun 30, 2024 Dec 31, 2022 Jun 30, 2022
    Revenue
    		 n/a n/a n/a
    Cost of Revenue
    		 n/a n/a n/a
    Gross Profit
    		 n/a n/a n/a
    Operating Income
    		 -7.31M -1.57M -1.69M
    Interest Income
    		 n/a 654.07K 1.43K
    Pretax Income
    		 -7.31M -915.46K -1.69M
    Net Income
    		 -7.31M -996.1K -1.69M
    Selling & General & Admin
    		 3.2M 1.37M 296.25K
    Research & Development
    		 4.11M n/a 1.39M
    Other Expenses
    		 n/a -201.31K n/a
    Operating Expenses
    		 7.31M 1.57M 1.69M
    Interest Expense
    		 n/a n/a n/a
    Selling & Marketing Expenses
    		 n/a n/a n/a
    Cost & Expenses
    		 7.31M 1.57M 1.69M
    Income Tax Expense
    		 1.63K 80.65K -235.14K
    Shares Outstanding (Basic)
    		 35.2M 5.76M 5.85M
    Shares Outstanding (Diluted)
    		 35.2M 5.76M 5.85M
    EPS (Basic)
    		 -0.21 -0.17 -0.29
    EPS (Diluted)
    		 -0.21 -0.17 -0.29
    EBITDA
    		 -7.31M -915.46K -247.72K
    EBIT
    		 -7.31M -915.46K -247.72K
    Depreciation & Amortization
    		 n/a 228.49K 236.56K

    Add to Watchlist